Comparative Pharmacology
Head-to-head clinical analysis: FLOMAX versus Q PAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOMAX versus Q PAM.
FLOMAX vs Q-PAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective antagonist of alpha-1A and alpha-1D adrenergic receptors in the prostate, bladder base, and bladder neck, leading to relaxation of smooth muscle and improved urinary flow.
Q-PAM is a quaternary ammonium neuromuscular blocking agent that competitively blocks acetylcholine at nicotinic receptors at the neuromuscular junction, causing depolarizing neuromuscular blockade.
0.4 mg orally once daily, approximately 30 minutes after the same meal each day. If no response after 2-4 weeks, may increase to 0.8 mg once daily.
100 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life is approximately 14-15 hours (range 6-20 hours) in healthy adults, allowing once-daily dosing.
Terminal half-life: 8-12 hours (mean 10 h) in healthy adults. Prolonged in renal impairment (up to 24 h in CrCl <30 mL/min); no dose adjustment needed in mild-moderate hepatic impairment.
Primarily hepatic metabolism (CYP3A4, CYP2D6) with <10% excreted unchanged in urine; fecal excretion accounts for ~76% of metabolites.
Renal: 60-70% unchanged; biliary/fecal: 20-30% as metabolites; total clearance ~12 L/h.
Category C
Category C
Alpha-1 Blocker
Alpha-1 Blocker